Seyed Yaghoub Moaddab

Seyed Yaghoub Moaddab

Auto-generated profile, based on publicly available information

Seyed Yaghoub Moaddab

Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
SGSima Ghaffari
Sima Ghaffari
AAAmin Abbasi
Amin Abbasi
MSMohammad Hossein Somi
Mohammad Hossein Somi
SMSeyed Yaghoub Moaddab
Seyed Yaghoub Moaddab
LNLeila Nikniaz
Leila Nikniaz
HLHamed Ebrahimzadeh Leylabadlo
Hamed Ebrahimzadeh Leylabadlo
Akkermansia muciniphila, a frequent colonizer in the gut mucous layer of individuals, has constantly been recognized as a promising candidate for the next generation of probiotics due to its biological advantages from in vitro and in vivo investigations. This manuscript comprehensively reviewed the features of A. muciniphila in terms of its function in host physiology and frequently utilized nutrition using the published peer-reviewed articles, which should present valuable and critical information to scientists, engineers, and even the general population. A. muciniphila is an important bacterium that shows host physiology. However, its physiological advantages in several clinical settings also have excellent potential to become a probiotic. Consequently, it can be stated that there is a coherent and direct relation between the biological activities of the gut microbiota, intestinal dysbiosis/eubiosis, and the population of A. muciniphila in the gut milieu, which is influenced by various genetical and nutritional factors. Current regulatory barriers, the need for large-scale clinical trials, and the feasibility of production must be removed before A muciniphila can be extensively used as a next-generation probiotic.

1 June 2019 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
VAVahideh Ebrahimzadeh Attari
Vahideh Ebrahimzadeh Attari
MSMohammad Hosein Somi
Mohammad Hosein Somi
MAMohammad Asghari Asghari-Jafarabadi
Mohammad Asghari Asghari-Jafarabadi
AOAlireza Ostadrahimi
Alireza Ostadrahimi
SMSeyed-Yaghob Moaddab
Seyed-Yaghob Moaddab
NLNeda Lotfi
Neda Lotfi
Purpose: The present study aimed to assess the effect of ginger (Zingiber officinale) powder supplementation on Helicobacter pylori eradication and improvement of dyspeptic symptoms in patients with H. pylori positive functional dyspepsia (FD). Methods: During this pilot study 15 patients with H. pylori positive FD received 3 g/d ginger powder as three 1-g tablets for 4-weeks. Dyspepsia symptoms were asked before and after the intervention using a questionnaire based on the Rome III criteria. H. pylori eradication was also assessed by a non-invasive stool antigen (HpSAg) test. Results: Ginger consumption accompanied by significant H. pylori eradication rate of 53.3% (P = 0.019) and the odds ratio (95% CI) was 8 (1.07 to 357.14). Moreover, our results showed significant changes in most of the dyspepsia symptoms after ginger supplementation. Conclusion: According to our findings, Z. officinale can be considered as a useful complementary therapy for FD. However, due to the small number of clinical trials in this area, further welldesigned clinical trials are needed to explicitly talk about its effectiveness especially about the eradication of H. pylori.

26 September 2022 in Critical Reviews in Food Science and Nutrition
Verified
Journal Article
Closed access
SZSevda Zoghi
Sevda Zoghi
AAAmin Abbasi
Amin Abbasi
FHFatemah Sadeghpour Heravi
Fatemah Sadeghpour Heravi
MSMohammad Hossein Somi
Mohammad Hossein Somi
ZNZeinab Nikniaz
Zeinab Nikniaz
HLHamed Ebrahimzadeh Leylabadlo
Hamed Ebrahimzadeh Leylabadlo
Celiac disease (CD) as a chronic gluten-sensitive intestinal condition, mainly affects genetically susceptible hosts. The primary determinants of CD have been identified as environmental and genetic variables. The development of CD is significantly influenced by environmental factors, including the gut microbiome. Therefore, gut microbiome re-programming-based therapies using probiotics, prebiotics, postbiotics, gluten-free diet, and fecal microbiota transplantation have shown promising results in the modification of the gut microbiome. Due to the importance and paucity of information regarding the CD pathophysiology, in this review, we have covered the association between CD development and gut microbiota, the effects of infectious agents, particularly the recent Covid-19 infection in CD patients, and the efficacy of potential therapeutic approaches in the CD have been discussed. Hence, scientific literature indicates that the diverse biological functions of the gut microbiota against immunomodulatory responses have made microbiome-based therapy an alternative therapeutic paradigm to ameliorate the symptoms of CD and quality of life. However, the exact potential of microbiota-based techniques that aims to quantitatively and qualitatively alter the gut microbiota to be used in the treatment and ameliorate the symptoms of CD will be determined with further research in the future.

23 March 2016 in Biochemical Genetics
Verified
Journal Article
Closed access
PDF file
SAShirin Azarbarzin
Shirin Azarbarzin
MFMohammad Ali Hosseinpour Feizi
Mohammad Ali Hosseinpour Feizi
RSReza Safaralizadeh
Reza Safaralizadeh
RRReyhaneh Ravanbakhsh
Reyhaneh Ravanbakhsh
MKMina Kazemzadeh
Mina Kazemzadeh
YMYaghoub Moaddab
Yaghoub Moaddab